Close

Stay informed

Drop us your email and we’ll keep you up-to-date on Medicaid issues.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Post ·

Medicare Must Not Cost Shift Alzheimer’s Care to Medicaid

NAMD explains the serious cost implications of Medicare’s coverage decision on the Alzheimer’s drug Aduhelm for state Medicaid programs.

Author
Program Stream

In a controversial decision, the Food and Drug Administration recently approved Aduhelm, a drug intended to treat Alzheimer’s disease. Now Medicare must decide if it will cover the drug, and its decision has significant cost implications for state Medicaid programs. If Medicare does not cover it and Medicaid becomes the primary source of coverage, NAMD estimates Medicaid spending for Aduhelm could increase by 250 percent or more. In this blog, NAMD’s Director of Federal Policy explains these potential implications.

Related resources

Stay Informed

Drop us your email and we’ll keep you up-to-date on Medicaid issues.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.